MedPath

Rectal Misoprostol Versus Sublingual Misoprostol Prior to Myomectomy

Phase 4
Completed
Conditions
Bleeding During Myomectomy
Interventions
Registration Number
NCT02716142
Lead Sponsor
Assiut University
Brief Summary

the aim of the study is To compare the effectiveness of rectally administered prostaglandin E1 synthetic analogue (misoprostol) 400 microgram versus sublingually administered misoprostol before myomectomy to decrease blood loss during and after the operation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
80
Inclusion Criteria
  • Patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging
  • Age ≥ 18 years and ≤ 50 years
  • Pre-operative hemoglobin >8 g/dl
  • Ability to understand and the willingness to sign a written informed consent.
  • Admissible medical/surgical history
  • Five or less symptomatic uterine myomas
  • All myomas are subserous or intramural.
  • Uterine size less than 24 weeks pregnancy
Exclusion Criteria
  • Patients who have had a prior abdominal myomectomy
  • Post-menopausal women
  • Patients with known bleeding/clotting disorders
  • Patients with a history of gynecologic malignancy
  • Hypertension.
  • Cardiac and Pulmonary diseases.
  • Obesity (body mass index > 30 kg/m2).
  • History of allergic reactions attributed to misoprostol
  • Cases that will require intraoperative conversion of myomectomy to hysterectomy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group Arectal misoprostolrectal misoprostol 400 microgram
Group Bsublingual misoprostolsublingual misoprostol 400 microgram
Primary Outcome Measures
NameTimeMethod
Mean amount of blood lossintraoperative
Secondary Outcome Measures
NameTimeMethod
Change of hemoglobin level24 hours

Trial Locations

Locations (1)

Ahmed Abbas

🇪🇬

Assiut, Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath